NEW YORK, June 20, 2017 /PRNewswire/ -- Deloitte today announced the debut of a global initiative to launch an innovative integrated solution for the pharmacovigilance capabilities of Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo). Powered by Deloitte's high-performance ConvergeHEALTH Safety™ platform, Daiichi Sankyo expects to significantly heighten the precision, depth and agility of insight extraction, enable proactive insight driven decision- making, and increase operational effectiveness across all of Daiichi Sankyo's global entities. Deloitte is also tasked with upgrading Daiichi Sankyo's existing transactional case processing system to deliver valuable efficiencies.
ConvergeHEALTH Safety's innovative capabilities and modern architecture will facilitate consolidation of multiple global systems into one and enhance Daiichi Sankyo's capabilities with advanced predictive analytics, global and Japanese aggregate reporting, and compliance monitoring capabilities. A transactional system upgrade will further enhance compliance monitoring and quality for adverse event case processing.
"With the increasing complexity of global regulatory and compliance requirements and the growing volume of adverse events, life sciences organizations require advanced capabilities across the pharmacovigilance life-cycle," says Greg Reh, principal, Deloitte Consulting LLP and global life sciences and health care leader. "The new solution will work to proactively and cost effectively address their complex business issues and processes around safety risk and compliance. It draws from Deloitte's hands-on experience with the safety domain, deep life sciences industry knowledge, our own technology intellectual property and continuous innovation with industry and academia."
To learn more about Deloitte's life sciences and health care industry practice visit the website.
Deloitte provides industry-leading audit, consulting, tax and advisory services to many of the world's most admired brands, including 80 percent of the Fortune 500 and more than 6,000 private and middle market companies. Our people work across more than 20 industry sectors to deliver measurable and lasting results that help reinforce public trust in our capital markets, inspire clients to make their most challenging business decisions with confidence, and help lead the way toward a stronger economy and a healthy society.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the "Deloitte" name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/daiichi-sankyo-co-ltd-selects-deloittes-convergehealth-safety-to-transform-and-upgrade-global-drug-safety-platform-300476579.html